Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016)

Niagen Bioscience has reported Liabilities from Discontinued Operations over the past 1 years, most recently at 184766.0 for Q4 2016.

Quarterly Liabilities from Discontinued Operations changed N/A to 184766.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was 184766.0 through Dec 2016, changed N/A year-over-year, with the annual reading at 184766.0 for FY2016, N/A changed from the prior year.
Liabilities from Discontinued Operations was 184766.0 for Q4 2016 at Niagen Bioscience.
Over five years, Liabilities from Discontinued Operations peaked at 184766.0 in Q4 2016 and troughed at 184766.0 in Q4 2016.